CDK4 and breast carcinoma: Here, we demonstrate a comprehensive analysis of the impact of RR inhibition by DDX in combination with the CDK4/6 inhibitor palbociclib on the cell cycle in parental and palbociclib-resistant ER+ and ER− breast cancer cells.